Cyagen Biosciences Suzhou Inc. closed a 285 million RMB (equivalent to about $41 million USD) Series B financing as of Feb 25. The investments are from funds managed by CMS Capital, GF Qianhe and GF Xinde which are both wholly owned by GF securities, and Guanghua Investment respectively.
Read More ›
Rensselaer, NY — July 18, 2018 - Cyagen Biosciences and Taconic Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.
Read More ›
Subscribe Now
Keep receiving FREE resources about research trends and promotional offers.
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy
